SetPoint Medical is sponsoring RESET RA, the US pivotal trial of its novel arthritis therapy, with $64m raised in a recent preferred stock financing.
SetPoint developed a proprietary vagus nerve stimulation system to amplify the immunoregulation effect of the spleen. By releasing specific neurotransmitters, such as acetylcholine, that bind to specific receptors on macrophages...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?